The impact of increased post-progression survival on the cost-effectiveness of interventions in oncology

Purpose: Cost-effectiveness analyses (CEA) of new technologies typically include “background” costs (eg, all “related” health care costs other than the specific technology under evaluation) as well as drug costs. In oncology, these are often expensive. The marginal cost-effectiveness ratio (ie, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Retzler, Jenny, Davies, Heather, Jenks, Michelle, Kiff, Christopher, Taylor, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504552/
https://www.ncbi.nlm.nih.gov/pubmed/31118714
http://dx.doi.org/10.2147/CEOR.S191382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504552/
https://www.ncbi.nlm.nih.gov/pubmed/31118714
http://dx.doi.org/10.2147/CEOR.S191382

Ejemplares similares